

## **AMENDMENTS TO THE SPECIFICATION**

Please amend the specification as follows. Paragraph numbers below refer to the paragraph numbers of U.S. Patent Publication No. US 2005-0261489 A1.

*Please amend the title as follows:*

Treatment Of Immune Disorders With Antibodies To Costimulating Polypeptide of T Cells, Monoclonal Antibodies, and The Preparation and Use Thereof

*Please insert the following new paragraph after paragraph [0006] of the specification:*

The present invention provides an isolated costimulating molecule (a) having the biological activity of costimulation of T cells, (b) which occurs on activated CD4+ and CD8+ T lymphocytes but not resting or activated B cells, granulocytes, monocytes, NK cells or dendritic cells, and (c) which has two polypeptide chains, the said molecule having a molecular weight of about 55 to 60 kDa determined in a nonreducing SDS polyacrylamide gel electrophoresis, and the two polypeptide chains of the said molecule having a molecular weight of about 27 kDa and about 29 kDa measured in a reducing SDS polyacrylamide gel electrophoresis. Use of substances which inhibit the biological activity of a costimulating molecule of the invention, such as monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, as pharmaceuticals is provided herein. Substances which inhibit the biological activity of a costimulating molecule of the invention can be used for the production of a pharmaceutical for the treatment of autoimmune diseases, for the prevention of rejection reactions in organ transplants and for the treatment of dysregulation of the immune system.

*Please insert the following new paragraph after paragraph [0098] of the specification:*

### **DEPOSIT OF HYBRIDOMA**

The hybridoma 8F4, secreting native monoclonal antibody 8F4, was deposited with the Deutsche Sammlung Von Mikroorganismen und ZellKulturen GmbH ("DSMZ"), at Mascheroder Weg 1b, D-3300 Braunschweig, Germany, on April 9, 2002, in compliance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the

Purposes of Patent Procedure on behalf of the Applicant and the Robert-Koch-Institut. The deposited hybridoma was assigned DSMZ accession number DSM ACC2539.